Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring

Ticagrelor is an antiplatelet agent prescribed to prevent the development of adverse cardiac events after acute coronary syndrome (ACS). According to the PLATO trial, ticagrelor is associated with ventricular pauses in the first week of treatment; however, these episodes were felt to be asymptomatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Munish, Mascarenhas, Daniel A. N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299195/
https://www.ncbi.nlm.nih.gov/pubmed/28246559
http://dx.doi.org/10.1155/2017/5074891
_version_ 1782505982923898880
author Sharma, Munish
Mascarenhas, Daniel A. N.
author_facet Sharma, Munish
Mascarenhas, Daniel A. N.
author_sort Sharma, Munish
collection PubMed
description Ticagrelor is an antiplatelet agent prescribed to prevent the development of adverse cardiac events after acute coronary syndrome (ACS). According to the PLATO trial, ticagrelor is associated with ventricular pauses in the first week of treatment; however, these episodes were felt to be asymptomatic and nonfatal to the patient. We present a case of ticagrelor related second-degree type II heart block causing severe dizziness and diaphoresis that resolved after discontinuation of the medication.
format Online
Article
Text
id pubmed-5299195
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-52991952017-02-28 Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring Sharma, Munish Mascarenhas, Daniel A. N. Case Rep Cardiol Case Report Ticagrelor is an antiplatelet agent prescribed to prevent the development of adverse cardiac events after acute coronary syndrome (ACS). According to the PLATO trial, ticagrelor is associated with ventricular pauses in the first week of treatment; however, these episodes were felt to be asymptomatic and nonfatal to the patient. We present a case of ticagrelor related second-degree type II heart block causing severe dizziness and diaphoresis that resolved after discontinuation of the medication. Hindawi Publishing Corporation 2017 2017-01-26 /pmc/articles/PMC5299195/ /pubmed/28246559 http://dx.doi.org/10.1155/2017/5074891 Text en Copyright © 2017 M. Sharma and D. A. N. Mascarenhas. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Sharma, Munish
Mascarenhas, Daniel A. N.
Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring
title Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring
title_full Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring
title_fullStr Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring
title_full_unstemmed Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring
title_short Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring
title_sort ticagrelor associated heart block: the need for close and continued monitoring
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299195/
https://www.ncbi.nlm.nih.gov/pubmed/28246559
http://dx.doi.org/10.1155/2017/5074891
work_keys_str_mv AT sharmamunish ticagrelorassociatedheartblocktheneedforcloseandcontinuedmonitoring
AT mascarenhasdanielan ticagrelorassociatedheartblocktheneedforcloseandcontinuedmonitoring

Ejemplares similares